Population pharmacokinetics and exposure–response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

Medicine, Oncology, Treatment Planning +14

Mutations of the BRAF gene in human cancer

Helen Davies, Graham R. Bignell, Charles Cox et al. · Nature · 2002 · 10.7K citations

Medicine, Genetics, Molecular Genetics +12

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

Keith T. Flaherty, Caroline Robert, Peter Hersey et al. · New England Journal of Medicine · 2012 · 2.1K citations · Full text

Medicine, Oncology, Pharmacology +17

Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models

Martin Bergstrand, Andrew C. Hooker, Johan Wallin et al. · The AAPS Journal · 2011 · 1.4K citations · Full text

Computing, Data Science, Data Visualization +5

Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

Keith T. Flaherty, Caroline Robert, Peter Hersey et al. · Zurich Open Repository and Archive (University of Zurich) · 2012 · 1.3K citations

Medicine, Oncology, Pharmacology +15